Preferences help
enabled [disable] Abstract
Number of results
2002 | 49 | 2 | 369-376
Article title

Analysis of mutations in the p16/ CDKN2A gene in sporadic and familial melanoma in the Polish population.

Title variants
Languages of publication
Mutations in CDKN2A have been found in sporadic cutaneous malignant (CMM), in familial CMM and in other syndromes associated with melanoma. In this study DNA was obtained from 207 individuals and five cell lines. There were 157 CMM patients and 50 healthy members of melanoma patients families. The CMM group included patients with one or two melanoma cases in the family, families with dysplastic nevus syndrom (DNS) and patients with a spectrum of other types of cancers in the family. PCR-SSCP analysis and sequencing identified: six substitutions in codon 58 CGA/TGA (Arg/Stop), 16 substitutions GAC/GAT in codon 84 (Asp/Asp), six substitutions CGA /TGA in codon 148 (Arg/Thr), 14 substitutions G/C in 3'UTR and 4 double changes (two in codon 84 and 3'UTR; two in codon 148 and 3'UTR). The mutation identified in codon 58 was found in tissue only. Other substitutions were polymorphisms found in DNA from tissue and blood samples. Most of them were identified in sporadic CMM (six in codon 148 Ala /Thr, 12 in codon 84 Asp/Asp and six in 3'UTR). The frequency of the polymorphisms was also high in DNS and CMM/DNS families (four in codon 84 Asp/Asp and six in 3'UTR). No mutations or polymorphisms were found in CMM patients with one or two melanoma cases and CMM patients, with other cancers in family history. The analysis of the CDKN2A gene mutations in the Polish population demonstrated: (i) no germline mutations; (ii) a relatively high number of genetic changes in sporadic melanoma; (iii) a high number of polymorphisms in DNS and CMM/DNS families.
Physical description
  • Department of Cancer Immunology, Chair of Oncology, K. Marcinkowski University of Medical Sciences, GreatPoland Cancer Center, Garbary 15, Poznań, Poland
  • Department of Cancer Immunology, Chair of Oncology, K. Marcinkowski University of Medical Sciences, GreatPoland Cancer Center, Garbary 15, Poznań, Poland
  • Department of Cancer Immunology, Chair of Oncology, K. Marcinkowski University of Medical Sciences, GreatPoland Cancer Center, Garbary 15, Poznań, Poland
  • Department of Cancer Immunology, Chair of Oncology, K. Marcinkowski University of Medical Sciences, GreatPoland Cancer Center, Garbary 15, Poznań, Poland
  • Burt EC, McGown G, Thorncroft M, James LA, Birth JM, Varley JM. (1999) Exclusion of the genes CDKN2 and PTEN as causative gene defects in Li-Fraumeni syndrome. Br J Cancer.; 80: 9-10.
  • Castellano M, Pollock PM, Walters MK, et al. (1997) CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res.; 57: 4868-75.
  • Ciotti P, Strigini P, Bianchi-Scarra G. (1996) Familial melanoma and pancreatic cancer. N Engl J Med.; 334: 469-70.
  • Fujimoto A, Morita R, Hatta N, et al. (1999) p16INK4a inactivation is not frequent in uncultured sporadic primary cutaneous melanoma. Oncogene.; 18: 2527-32.
  • Goldstein AM, Struewing JP, Chidambaram A. (2000) Genotype-phenotype relationships in U.S. melanoma - prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst.; 92: 1006-10.
  • Hashemi J, Bendahl PO, Sanberg T, et al. (2001) Haplotype analysis and age estimation of the 113insR CDKN2A founder mutation in Swedish melanoma families. Genes Chromosomes Cancer.; 31: 107-16.
  • Hayward N. (2000) New development in melanoma genetics. Curr Oncol Rep.; 2: 300-6.
  • Herman JG, Graff JR, Myohanen S, et al. (1996) Methylation-specific PCR: a novel assay for methylation status of CpG islands. Proc Natl Acad Sci U S A.; 93: 9821-6.
  • Holland EA, Beaton SC, Becker TM, et al. (1995) Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene.; 11: 2289-94.
  • Holuska FG, Hodi FS. (1998) Molecular genetics of familial cutaneous melanoma. J Clin Oncol.; 2: 670-82.
  • Kamb A, Gruis NA, Weaver-Feldhaus J, et al. (1994a) A cell cycle regulator potentially involved in genesis of many tumor types. Science.; 264: 436-40.
  • Kamb A, Shattuck-Ediens D, Eeles R, et al. (1994b) Analysis of the p16 gene (CDKN2) as candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet.; 8: 23-6.
  • Koph AW, Hellman LJ, Rogers GS. (1986) Familial malignant melanoma. JAMA.; 256: 1915-9.
  • Kumar R, Smeds J, Berggren P, et al. (2001) A single nucleotide polymorphism in the 3' untranslated region of CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 are rare. Int J Cancer.; 95: 388-93.
  • Lee JY, Dong SM, Shin MS, et al. (1997) Genetic alternations of p16INK4a and p13 genes in sporadic dysplastic nevus. Biochem Biophys Res Commun.; 237: 667-72.
  • Lukas J, Parry D, Aagaard L, et al. (1995) Retinoblastoma - protein-depended cell-cycle inhibition by the tumor suppressor p16 Nature.; 375: 503-6.
  • Lynch HT, Brand RE, Hogg D, et al. (2002) Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma - prone families: the familial atypical multiple mole melanoma - pancreatic carcinoma syndrome. Cancer.; 94: 84-6.
  • MacKie RM, Andrew N, Lanyon WG, Connor JM. (1998) CDKN2A germline mutations in U. K. patients with familial melanoma and multiple primary melanomas. J Invest Dermatol.; 111: 269-72.
  • Morita R, Fujimoto A, Hatta N, et al. (1998) Comparision of genetic profiles between primary melanomas and their metastases reveals genetic alterations and clonal evolution during progression. J Invest Dermatol.; 111: 919-24.
  • Puig S, Ruiz A, Castel T, et al. (1997) Inherited susceptibility to sever cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in melanoma family with a mutation in the CDKN2A (P16INK4A) gene. Hum Genet.; 101: 359-364.
  • Quelle DE, Zindy F, Ashmun RA, Sherr CJ. (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell.; 83: 993-1000.
  • Reed JA, Loganzo Jr F, Shea CR, et al. (1995) Loss of expression of the p16/cyclin-depended kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res.; 55: 2713-8.
  • Rizos H, Darmanian AP, Holland EA, et al. (2001a) Mutations in the INK4a/ARF melanoma susceptibility locus functionally impair p14ARF. J Biol Chem.; 276: 41424-34.
  • Rizos H, Puigi S, Badenas C, et al. (2001b) A melanoma-associated germline mutation in exon 1beta inactivates p14ARF. Oncogene.; 20: 5543-7.
  • Ruiz A, Puig S, Lynch M, et al. (1998) Retention of CDKN2A locus and low frequency of point mutations in primary and metastatic cutaneous malignant melanoma. Int J Cancer.; 76: 312-6.
  • Serrano M, Hannon GJ, Beach D. (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature.; 366: 704-7.
  • Shennan MG, Badin AC, Walsh S, et al. (2000) Lack of germline CDK2a mutations in familial melanoma. Oncogene.; 19: 1849-52.
  • Sherr CJ. (1996) Cancer cell cycle. Science.; 274: 1672-7.
  • Smith-Sorensen B, Hovig E. (1996) CDKN2A (p16/INK4a) somatic and germline mutations. Hum Mutat.; 7: 294-303.
  • Stone S, Jing P, Dayanath P, et al. (1995) Complex structure and regulation of the p16 (MTS) locus. Cancer Res.; 55: 2995-7.
  • Stott FJ, Bates S, James MC, et al. (1998) The alternative product from human CDKN2A locus, p14ARF participates in regulatory feedback loop with p53 and MDM2. EMBO J.; 17: 5001-14.
  • Tsao O, Zhang X, Kwitkiwski K, Finkelstein DM, Sober AJ, Haluska FG.. (2000) Low prevalence of germline CDKN2A and CDK4 mutations in patients with early - onset melanoma. Arch Dermatol.; 136: 1118-22.
  • Yakobson E, Shemesh P, Azizi E, et al. (2000) Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. Eur J Hum Genet.; 8: 590-6.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.